TechSparks 2025 returns to Bengaluru with a powerhouse lineup of policymakers, founders, and investors. Set to take place ...

Federal regulators are trying to make it easier to develop cheaper alternatives to powerful drugs that many Americans depend ...

The goal of gene therapy is to permanently cure hereditary diseases. One of the most promising technologies for this is the ...

Sana Biotechnology, Inc. is a Strong Buy with promising cell therapies for diabetes & B-cell disorders. Click here to find out why SANA stock is a Strong Buy.

The company’s technology, a modified herpes simplex virus used to deliver gene therapies, was given the FDA’s new designation ...

Narrated by Mark Ruffalo with insights from Walter Isaacson, Cracking the Code: Phil Sharp and the Biotech Revolution follows ...

Biogen will pay a Chicago biotech $70 million upfront, plus up to $990 million in milestone payments, for an early-stage ...

GRAIL's financial position is reinforced by $435 million in new funding, including strategic backing from Samsung for ...

HIGHLIGHTS:Meridian Mining’s Cabaçal Au-Cu-Ag Project’s Preliminary Licence (“PL”) approved by CONSEMA Council Meeting:Mato ...

Assays for three holes from the Pepas MRE infill and metallurgical program include: PEP065 - 33.3m @ 2.84g/t Au PEP065B - ...

A new year means a new Fierce Biotech Fundraising Tracker to record the significant amounts of venture capital being funneled into the industry. We're maintaining the criteria we used for last year's ...

Nascent cardiovascular biotech Kardigan is continuing its bumper year with a pulse-quickening $254 million series B fundraising round, bringing the company’s total financing to more than half a ...